Modulation of the Renin-Angiotensin-aldosterone system in heart failure

J. George, A. D. Struthers, C. C. Lang (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


The renin-angiotensin-aldosterone system (RAAS) is well-established and continues to be pursued as a therapeutic target in the treatment of heart failure, predominantly due to the success of agents that block RAAS in clinical trials of systolic heart failure. The optimal treatment of heart failure patients with preserved ejection fraction (HFpEF), however, remains unclear. Early trials of direct renin inhibitors have suggested that these agents may play a role in HFpEF, but recent clinical trial results have not been encouraging. Preliminary trials of angiotensin-receptor/neprilysin inhibitors look promising. Whether results with these or other drugs will alter current recommendations remains to be seen. In this review, we assess the current understanding of the role of RAAS modulation in heart failure.
Original languageEnglish
Pages (from-to)403
Number of pages1
JournalCurrent Atherosclerosis Reports
Issue number4
Publication statusPublished - Apr 2014


Dive into the research topics of 'Modulation of the Renin-Angiotensin-aldosterone system in heart failure'. Together they form a unique fingerprint.

Cite this